title: Systemic and renal haemodynamic changes in renal schemia/reperfusion injury: impact of erythropoietin.
abstract: The objective of this study was to investigate the effects of erythropoietin (EPO) on systemic and renal hemodynamics in a rat model of renal ischemic/reperfusion (I/R) injury. We used 30 male Sprague-Dawley rats distributed among the following 3 groups (10 rats per group): (i) the sham-operated group, (ii) the control group (I/R injury only), and (iii) the EPO-treated group (I/R injury with 1500 U EPO·(kg body mass)⁻¹ on day 0, and 500 U·kg⁻¹ on days 2 and 4 after ischemia). Renal function, arterial blood pressure (ABP), renal plasma flow (RPF), renal blood flow (RBF), and renal vascular resistance (RVR) were measured on days 1, 2, and 7 after ischemia. The expression of endothelial NO synthase (eNOS) and histopathology of kidney were evaluated on day 7. The contractility of aortic strips was recorded from the different groups. The results show that renal function and histopathology were significantly improved after treatment with EPO. Compared with the control group, the EPO-treated group showed a significant increase in RPF, RBF, haematocrite, ABP, eNOS expression, and a decrease in RVR (p < 0.05).The response of aortic strips to the relaxant effect of acetylcholine was improved in the EPO-treated group. In conclusion, treatment with EPO improves renal function and renal haemodynamics in renal I/R injury, and causes significant rise of ABP and haematocrite value.
authors.affiliation: Department of Physiology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. zizomenna@yahoo.com
authors.forename: Abdel-Aziz M
authors.initials: AA
authors.lastname: Hussein
authors.forename: Nashwa
authors.initials: N
authors.lastname: Barakat
authors.forename: Amira
authors.initials: A
authors.lastname: Awadalla
authors.forename: Ahmed A
authors.initials: AA
authors.lastname: Shokeir
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000503:physiopathology; D004351:Drug Resistance / Q000187:drug effects; D004790:Enzyme Induction / Q000187:drug effects; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D007022:Hypotension / Q000209:etiology / Q000517:prevention & control*; D007511:Ischemia / Q000188:drug therapy*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D020030:Nitric Oxide Donors / Q000494:pharmacology; D052250:Nitric Oxide Synthase Type III / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D020011:Protective Agents / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012079:Renal Circulation / Q000187:drug effects*; D015427:Reperfusion Injury / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D006397:Hematinics; D020030:Nitric Oxide Donors; D020011:Protective Agents; D011994:Recombinant Proteins; D014665:Vasodilator Agents; D004921:Erythropoietin; D000068817:Epoetin Alfa; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat